Chimeric CLL-1 antibody fusion proteins containing granulocyte- macrophage colony-stimulating factor or interleukin-2 with specificity for B- cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties

Blood

Volumn 89, Issue 12, 1997, Pages 4437-4447

  Hornick, Jason L ^b   Khawli, Leslie A ^b   Hu, Peisheng ^b   Lynch, Maureen ^b   Anderson, Peter M ^b   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2;

ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN SPECIFICITY; ARTICLE; B CELL LYMPHOMA; CELL FUNCTION; CHIMERA; EFFECTOR CELL; GENE TARGETING; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; TISSUE DISTRIBUTION; TUMOR GROWTH; XENOGRAFT;

EID: 0030974616     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.12.4437     Document Type: Article

References (55)

1. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457, 1994
2. Dillman RO: Antibodies as cytotoxic therapy. J Clin Oncol 12:1497, 1994
3. Wilder RB, DeNardo GL, DeNardo SJ: Radioimmunotherapy: Recent results and future directions. J Clin Oncol 14:1383, 1996
4. Bianchi AC, Heslop HE, Veys P, Macey M, Holland M, Prentice HG, Brenner MK: Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and GM-CSF. Br J Haematol 73:468, 1989
5. Vuist WMJ, Buitenen Fv, de Rie MA, Hekman A, Rümke P, Melief CJM: Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model. Cancer Res 49:3783, 1989
6. Gill I, Agah R, Hu E, Mazumder A: Synergistic antitumor effects of interleukin 2 and the monoclonal Lym-1 against human Burkitt lymphoma cells in vitro and in vivo. Cancer Res 49:5377, 1989
7. Biddle WC, Pancook J, Goldrosen M, Han T, Foon KA, Vaickus L: Antibody-dependent, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: Effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors. Cancer Res 50:2991, 1990
8. Hooijberg E, Sein JJ, van den Berk PCM, Hart AAM, van der Valk MA, Kast WM, Melief CJM, Hekman A: Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2. Cancer Res 55:2627, 1995
9. Ottonello L, Morone P, Dapino P, Dallegri F: Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes. Blood 87:5171, 1996
10. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397, 1990
11. Tsai S-CJ, Gansbacher B, Tait L, Miller FR, Heppner GH: Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J Natl Cancer Inst 85:546, 1993
12. Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L: Immunotherapy via gene therapy: Comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-γ genes. J Immunother Emphasis Tumor Immunol 14:191, 1993
13. Cignetti A, Guarini A, Carbone A, Forni M, Cronin K, Forni G, Gansbacher B, Foa R: Transduction of the IL2 gene into human acute leukemia cells: Induction of tumor rejection without modifying cell proliferation and IL2 receptor expression. J Natl Cancer Inst 86:785, 1994
14. Visseren MJW, Koot M, van der Voort EIH, Gravestein LA, Schoenmakers HJ, Kast WM, Zijlstra M, Melief CJM: Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunity. J Immunother 15:119, 1994
15. Katsanis E, Orchard PJ, Bausero MA, Gorden KB, McIvor RS, Blazar BR: lnterleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors. J Immunother 15:81, 1994
16. Allione A, Consalvo M, Nanni P, Lollini PL, Cavallo F, Giovarelli M, Forni M, Gulino A, Colombo MP, Dellabona P, Hock H, Blankenstein T, Rosenthal FM, Gansbacher B, Bosco MC, Musso T, Gusella L, Forni G: Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-7, IL-10, tumor necrosis factor a, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res 54:6022, 1994
17. Gunji Y, Tagawa M, Matsubara H, Takenaga K, Shimada H, Kondo F, Suzuki T, Nakajima K, Aoki T, Asano T, Ochiai T, Isono K, Kageyama H, Nakamura Y, Sakiyama S: Murine colon carcinoma cells engineered to produce human interleukin-2 induce tumor-specific anti-tumor response. Int J Cancer 66:135, 1996
18. Gillies SD, Reilly EB, Lo K-M, Reisfeld RA: Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci USA 89:1428, 1992
19. Fell HP, Gayle MA, Grosmaire L, Ledbetter JA: Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab') with specificity for carcinomas and human 1L-2. J Immunol 146:2446, 1991
20. Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA: A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 91:9626, 1994
21. Epstein AL, Marder RJ, Winter JN, Stathopoulos E, Chen F-M, Parker JW, Taylor CR: Two new monoclonal antibodies. Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 47:830, 1987
22. Lee F, Yokota T, Otsuka T, Gemmell L, Larson N, Luh J, Arai K, Rennick D: Isolation of cDNA for a human granulocytemacrophage colony-stimulating factor by functional expression in mammalian cells. Proc Natl Acad Sci USA 82:4360, 1985
23. Cullen BR: Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism. Cell 46:973, 1986
24. Hu P, Glasky MS, Yun A, Alauddin MM, Hornick JL, Khawli LA, Epstein AL: A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system. Hum Antibodies Hybridomas 6:57, 1995
25. Epstein AL, Chen F-M, Taylor CR: A novel method for the detection of necrotic lesions in human cancers. Cancer Res 48:5842, 1988
26. Burk KH, Drewinko B, Trujillo JM, Aheam MJ: Establishment of a human plasma cell line in vitro. Cancer Res 38:2508, 1978
27. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680, 1970
28. Epstein AL, Marder RJ, Winter JN, Fox RI: Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors. J Immunol 133:1028, 1984
29. Frankel ME, Gerhard W: The rapid determination of binding constants for antiviral antibodies by a radioimmunoassay: An analysis of the interaction between hybridoma proteins and influenza virus. Mol Immunol 16:101, 1979
30. Anderson PM, Rogosheske JR, Ramsay NKC, Weisdorf DJ: Biological activity of recombinant interleukin-2 in intravenous admixtures containing antibiotic, morphine sulfate, or total parenteral nutrient solution. Am J Hosp Pharm 49:608, 1992
31. Korzeniewski C, Callewaert DM: An enzyme-release assay for natural cytotoxicity. J Immunol Methods 64:313, 1983
32. Elsässer D, Valerius T, Repp R, Weiner GJ, Deo Y, Kalden JR, van de Winkel JGJ, Stevenson GT, Glennie MJ, Gramatzki M: HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood 87:3803, 1996
33. Steplewski Z, Sun LK, Shearman CW, Ghrayeb J, Daddona P, Koprowski H: Biological activity of human-mouse IgG1. IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci USA 85:4852, 1988
34. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM: Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells. Immunol Lett 39:91, 1994
35. Hu P, Hornick JL, Glasky MS, Yun A, Milkie MN, Khawli LA, Anderson PM, Epstein AL: A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake. Cancer Res 56:4998, 1996
36. Ragnhammar P, Frödin J-E, Trotta PP, Mellstedt H: Cytotoxicity of white blood cells activated by granulocyte-coJony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies. Cancer Immunol Immunother 39:254, 1994
37. Singh SM, Sone S, Inamura N, Ogura T: Up-regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes. Int J Cancer 44:170, 1989
38. Masucci G, Ragnhammar P, Wersäll P, Mellstedt H: Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A). Cancer Immunol Immunother 31:231, 1990
39. Baldwin GC, Chung GY, Kaslander C, Esmail T, Reisfeld RA, Golde DW: Colony-stimulating factor enhancement of myeloid effector cell cytotoxicity towards neuroectodermal tumour cells. Br J Haematol 83:545, 1993
40. Kushner BH, Cheung N-KV: GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 73:1936, 1989
41. Ragnhammar P, Fagerberg J, Frödin J-E, Hjelm A-L, Lindemalm C, Magnusson I, Masucci G, Mellstedt H: Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma - Long-lasting, complete remissions can be induced, Int J Cancer 53:751, 1993
42. Gillies SD, Young D, Lo K-M, Roberts S: Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjug Chem 4:230, 1993
43. Rosenstein M, Ertinghausen SE, Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. Immunology 137:1735, 1986
44. Damle NK, Doyle LV: LL-2 activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers, J Immunol 142:2660, 1989
45. Ohkubo C, Bigos D, Jain RK: Interleukin 2-induced leukocyte adhesion to the normal and tumor microvasculature endothelium in vivo and its inhibition by dextran sulfate: Implications for vascular leak syndrome. Cancer Res 51:1561, 1991
46. Edwards MJ, Miller FN, Sims DE, Abney DL, Schuschke DA, Corey TS: Interleukin 2 acutely induces platelet and neutrophilendothelial adherence and macromolecular leakage. Cancer Res 52:3425, 1992
47. Savage P, So A, Spooner RA, Epenetos AA: A recombinant single chain antibody interleukin-2 fusion protein. Br J Cancer 67:304, 1993
48. Xiang J, Liu E, Moyana T, Qi Y: Single-chain antibody variable region-targeted interleukin-2 stimulates T cell killing of human colorectal carcinoma cells. Immunol Cell Biol 72:275, 1994
49. Bei R, Schlom J, Kashmiri SVS: Baculovirus expression of a functional single-chain immunoglobulin and its IL-2 fusion protein. J Immunol Methods 186:245, 1995
50. Tao M-H, Levy R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755, 1993
51. Chen TT, Tao M-H, Levy R: Idiotype-cytokine fusion proteins as cancer vaccines: Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 153:4775, 1994
52. Pancook JD, Becker JC, Gillies SD, Reisfeld RA: Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Cancer Immunol Immunother 42:88, 1996
53. Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA: An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci USA 93:7826, 1996
54. Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA: Long-lived and transferable tumor immunity in mice following targeted interleukin 2 therapy. J Clin Invest 98:2801, 1996
55. Becker JC, Pancook JD, Gillies SD, Furukawa K, Reisfeld RA: T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 183:2361, 1996